NZ566807A - Novel crystal forms of irinotecan hydrochloride - Google Patents

Novel crystal forms of irinotecan hydrochloride

Info

Publication number
NZ566807A
NZ566807A NZ566807A NZ56680706A NZ566807A NZ 566807 A NZ566807 A NZ 566807A NZ 566807 A NZ566807 A NZ 566807A NZ 56680706 A NZ56680706 A NZ 56680706A NZ 566807 A NZ566807 A NZ 566807A
Authority
NZ
New Zealand
Prior art keywords
irinotecan hydrochloride
irinotecan
forms
crystalline form
hydrochloride
Prior art date
Application number
NZ566807A
Other languages
English (en)
Inventor
Shu-Ping Chen
Piin-Jye Harn
Original Assignee
Scinopharm Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scinopharm Singapore Pte Ltd filed Critical Scinopharm Singapore Pte Ltd
Publication of NZ566807A publication Critical patent/NZ566807A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ566807A 2005-09-20 2006-09-19 Novel crystal forms of irinotecan hydrochloride NZ566807A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71882705P 2005-09-20 2005-09-20
PCT/US2006/036437 WO2007035709A2 (en) 2005-09-20 2006-09-19 Novel crystal forms of irinotecan hydrochloride

Publications (1)

Publication Number Publication Date
NZ566807A true NZ566807A (en) 2011-05-27

Family

ID=37889452

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ566807A NZ566807A (en) 2005-09-20 2006-09-19 Novel crystal forms of irinotecan hydrochloride

Country Status (14)

Country Link
US (1) US7435818B2 (enExample)
EP (2) EP2082741A1 (enExample)
JP (1) JP5119153B2 (enExample)
KR (1) KR101150504B1 (enExample)
CN (1) CN101277694B (enExample)
AR (1) AR056082A1 (enExample)
AT (1) ATE460162T1 (enExample)
AU (1) AU2006292328B2 (enExample)
BR (1) BRPI0616308A2 (enExample)
CA (1) CA2623117C (enExample)
DE (1) DE602006012871D1 (enExample)
ES (1) ES2343204T3 (enExample)
NZ (1) NZ566807A (enExample)
WO (1) WO2007035709A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101318964B (zh) * 2007-06-07 2010-12-15 上海迪赛诺医药发展有限公司 盐酸伊立替康新晶型及其制备方法
US7572803B2 (en) * 2007-10-25 2009-08-11 The Christus Stehlin Foundation For Cancer Research Hydrated crystalline esters of camptothecin
IT1391757B1 (it) * 2008-11-11 2012-01-27 Antibioticos Spa Irinotecan cloridrato cristallino e metodi per la sua preparazione
US8546573B2 (en) 2009-11-18 2013-10-01 Cadila Healthcare Limited Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate
WO2012007952A1 (en) * 2010-07-12 2012-01-19 Hetero Research Foundation Novel polymorph of irinotecan hydrochloride
CN102311443B (zh) * 2011-08-24 2014-07-16 上海北卡医药技术有限公司 盐酸伊立替康的新晶型及其制备方法
CN102617584B (zh) * 2012-03-14 2013-10-16 海南锦瑞制药股份有限公司 一种盐酸伊立替康化合物及其药物组合物
CN102850363B (zh) * 2012-09-18 2013-07-10 山东罗欣药业股份有限公司 盐酸伊立替康化合物及其药物组合物
CA2909642A1 (en) * 2013-04-15 2014-10-23 Regeneron Pharmaceuticals, Inc. Markers of tumor cell response to anti-cancer therapy
CN105713004A (zh) * 2016-03-23 2016-06-29 杭州华东医药集团新药研究院有限公司 一种高品质盐酸伊立替康三水合物晶型的制备方法
US10919905B2 (en) * 2019-05-16 2021-02-16 Scinopharm Taiwan, Ltd. Polymorphism for irinotecan free base

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
MA24682A1 (fr) * 1997-10-23 1999-07-01 Smithkline Beecham Corp Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
DE60314378T2 (de) * 2002-03-01 2008-02-28 Pfizer Italia S.R.L. Kristalline polymorphe form von irinotecanhydrochlorid
CZ20022250A3 (cs) * 2002-06-27 2004-02-18 Pliva-Lachema A. S. Způsob výroby irinotekanu
KR101095382B1 (ko) 2003-02-25 2011-12-16 가부시키가이샤 야쿠르트 혼샤 이리노테칸 염산염의 결정다형의 제조방법
WO2006016203A1 (en) * 2004-08-09 2006-02-16 Shilpa Medicare Limited An improved process for the preparation of irinotecan hydrochloride trihydrate
US20060046993A1 (en) * 2004-09-01 2006-03-02 Pharmacia Italia S.P.A. Crystalline polymorphic form of irinotecan hydrochloride
EP1846412B1 (en) * 2005-02-07 2009-10-21 Fermion Oy Process for the manufacturing of 7-ethyl-10-hydroxy camptothecin
JP5133704B2 (ja) * 2005-02-08 2013-01-30 フェルミオン オサケ ユキチュア 製造方法

Also Published As

Publication number Publication date
CN101277694A (zh) 2008-10-01
EP1951235B1 (en) 2010-03-10
EP2082741A1 (en) 2009-07-29
BRPI0616308A2 (pt) 2011-06-14
ES2343204T3 (es) 2010-07-26
AU2006292328A1 (en) 2007-03-29
CA2623117A1 (en) 2007-03-29
CN101277694B (zh) 2011-04-20
JP2009508874A (ja) 2009-03-05
JP5119153B2 (ja) 2013-01-16
WO2007035709A2 (en) 2007-03-29
US20070072890A1 (en) 2007-03-29
KR20080059244A (ko) 2008-06-26
AU2006292328B2 (en) 2012-12-20
EP1951235A4 (en) 2008-10-29
WO2007035709A3 (en) 2007-10-25
AR056082A1 (es) 2007-09-19
CA2623117C (en) 2013-12-10
EP1951235A2 (en) 2008-08-06
ATE460162T1 (de) 2010-03-15
US7435818B2 (en) 2008-10-14
DE602006012871D1 (de) 2010-04-22
KR101150504B1 (ko) 2012-07-09

Similar Documents

Publication Publication Date Title
EP1487840B1 (en) Crystalline polymorphic form of irinotecan hydrochloride
KR20230019110A (ko) 4-아미노-5-(6-(4-메틸피페라진-1-일)-1H-벤조[D]이미다졸-2-일)티에노[2,3-b]피리딘-6(7H)-온(one)의 염 및 결정형
CA2623117C (en) Novel crystal forms of irinotecan hydrochloride
KR20140076979A (ko) 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
JP7314319B2 (ja) Ｃｄｋ９阻害剤の結晶多形体及びその製造方法と用途
KR101208956B1 (ko) 엘로티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물
RU2352572C2 (ru) Пентагидрат моногидрохлорида топотекана в кристаллической форме, соответствующие композиции на их основе, способы получения и/или способы лечения
KR20190137116A (ko) Eoc315 mod. i 결정형의 화합물 및 이의 제조방법
RU2561118C2 (ru) Производные камптотецина, обладающие противоопухолевой активностью
US8349863B2 (en) Crystalline polymorphic form of a camptothecin analogue
WO2019001307A1 (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
HK40064722A (en) Polymorph of cdk9 inhibitor and preparation method for polymorph and use thereof
ZA200603508B (en) Novel compound, corresponding compositions, preparation and/or treatment methods

Legal Events

Date Code Title Description
PSEA Patent sealed